Vinay Prasad

Associate Professor

  • 2690 Citations
  • 26 h-Index
20092019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2009 2019

Filter
Comment/debate
2019

A reality check of the accelerated approval of immune-checkpoint inhibitors

Gill, J. & Prasad, V., Jan 1 2019, (Accepted/In press) In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Cancer screening: A modest proposal for prevention

Kim, M. S., Nishikawa, G. & Prasad, V., Mar 1 2019, In : Cleveland Clinic journal of medicine. 86, 3, p. 157-160 4 p.

Research output: Contribution to journalComment/debate

Open Access
Early Detection of Cancer

Registration studies — when should patients be deemed ineligible for aggressive therapy?

Cook, R. J., Gill, J. & Prasad, V., Jan 1 2019, In : Nature Reviews Clinical Oncology.

Research output: Contribution to journalComment/debate

Therapeutics

Testing for blinding in sham-controlled studies for procedural interventions: The third-party video method

Gill, J. & Prasad, V., Mar 11 2019, In : CMAJ. 191, 10, p. E272-E273

Research output: Contribution to journalComment/debate

2018
3 Citations (Scopus)

Choice of control group in randomised trials of cancer medicine: are we testing trivialities?

Tao, D. & Prasad, V., Sep 1 2018, In : The Lancet Oncology. 19, 9, p. 1150-1152 3 p.

Research output: Contribution to journalComment/debate

Medicine
Control Groups
Neoplasms
4 Citations (Scopus)

Concerns about the approval of nusinersen sodium by the US food and drug administration

Gerrity, M. S., Prasad, V. & Obley, A. J., Jun 1 2018, In : JAMA Internal Medicine. 178, 6, p. 743-744 2 p.

Research output: Contribution to journalComment/debate

United States Food and Drug Administration
Sodium
7 Citations (Scopus)

Improving observational studies in the era of big data

Gill, J. & Prasad, V., Sep 1 2018, In : The Lancet. 392, 10149, p. 716-717 2 p.

Research output: Contribution to journalComment/debate

Observational Studies
6 Citations (Scopus)

Pemetrexed in nonsquamous non-small-cell lung cancer: The billion dollar subgroup analysis

Gyawali, B. & Prasad, V., Jan 1 2018, In : JAMA oncology. 4, 1, p. 17-18 2 p.

Research output: Contribution to journalComment/debate

Pemetrexed
Non-Small Cell Lung Carcinoma
38 Citations (Scopus)

Tisagenlecleucel - The first approved CAR-T-cell therapy: Implications for payers and policy makers

Prasad, V., Jan 1 2018, In : Nature Reviews Clinical Oncology. 15, 1, p. 11-12 2 p.

Research output: Contribution to journalComment/debate

Cell- and Tissue-Based Therapy
Administrative Personnel
T-Lymphocytes
2017
4 Citations (Scopus)

Combining drugs and extending treatment-a PFS end point is not sufficient

Gyawali, B. & Prasad, V., Sep 1 2017, In : Nature Reviews Clinical Oncology. 14, 9, p. 521-522 2 p.

Research output: Contribution to journalComment/debate

Pharmaceutical Preparations
6 Citations (Scopus)

Drugs that lack single-agent activity: Are they worth pursuing in combination?

Gyawali, B. & Prasad, V., Apr 1 2017, In : Nature Reviews Clinical Oncology. 14, 4, p. 193-194 2 p.

Research output: Contribution to journalComment/debate

Pharmaceutical Preparations
6 Citations (Scopus)

Overestimating the Benefit of Cancer Drugs

Prasad, V., Dec 1 2017, In : JAMA Oncology. 3, 12, p. 1737-1738 2 p.

Research output: Contribution to journalComment/debate

Drug Evaluation
Antineoplastic Agents
Quality of Life
Pharmaceutical Preparations
Neoplasms
3 Citations (Scopus)

Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?

Goldstein, D. A., Bilal, U. & Prasad, V., Oct 15 2017, In : Cancer. 123, 20, p. 3872-3874 3 p.

Research output: Contribution to journalComment/debate

Lung Neoplasms
Ligands
Therapeutics
pembrolizumab
2016
99 Citations (Scopus)

Perspective: The precision-oncology illusion

Prasad, V., Sep 7 2016, In : Nature. 537, 7619, p. S63

Research output: Contribution to journalComment/debate

Molecular Targeted Therapy
Precision Medicine
Medical Oncology
Genetic Testing
Reproducibility of Results

Precision medicine in diffuse large B-cell lymphoma: Hype or hope?

Prasad, V., Nov 1 2016, In : European Journal of Cancer. 68, p. 22-26 5 p.

Research output: Contribution to journalComment/debate

Precision Medicine
Lymphoma, Large B-Cell, Diffuse
3 Citations (Scopus)

Same data; Different interpretations

Bishal Gyawali, G. & Prasad, V., Nov 1 2016, In : Journal of Clinical Oncology. 34, 31, p. 3729-3732 4 p.

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Thinking systematically about the off-label use of cancer drugs and combinations for patientswho have exhausted proven therapies

Mailankody, S. & Prasad, V., Sep 1 2016, In : Oncologist. 21, 9, p. 1031-1032 2 p.

Research output: Contribution to journalComment/debate

Off-Label Use
Drug Combinations
Neoplasms
Therapeutics